Trial | NCT02085824  Report issue

Official Title

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    60
The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
Study Started
Jul 31
2012
Primary Completion
Apr 30
2014
Anticipated
Study Completion
Apr 30
2014
Anticipated
Last Update
Mar 14
2014
Estimate

Drug Enoxaparin

Drug rivaroxaban

Drug dabigatran

enoxaparin Experimental

enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days

rivaroxaban Experimental

rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery

dabigatran Experimental

dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery

Criteria 

Inclusion Criteria:

primary, end-stage hip osteoarthritis requiring total hip arthroplasty

Exclusion Criteria:

inflammatory arthropathies
liver disorders
neoplastic conditions
clotting disorders
No Results Posted